Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed
that aberrant PPIs are associated with various diseases, including cancer, infectious …

RAS proteins require membrane association for their biologic activity, making this
association a logical target for anti-RAS therapeutics. Lipid modification of RAS proteins by a …

Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …

Benzimidazole, a fused heterocycle bearing benzene and imidazole has gained
considerable attention in the field of contemporary medicinal chemistry. The moiety is of …

Targeting protein–protein interactions (PPIs) has emerged as a viable approach in modern
drug discovery. However, the identification of small molecules enabling us to effectively …

A metal–organic framework [MIL-101 (Cr)] was used as an efficient heterogeneous catalyst
in the synthesis of benzoazoles (benzimidazole, benzothiazole, and benzoxazole), and …

RAS proteins have traditionally been deemed undruggable, as they do not possess an
active site to which small molecules could bind but small molecules that target one form of …

The three human RAS genes encode four proteins that play central roles in oncogenesis by
acting as binary molecular switches that regulate signaling pathways for growth and …

Covalent labeling of amino acids in proteins by reactive small molecules, in particular at
cysteine SH and lysine NH groups, is a powerful approach to identify and characterize …

Within the MAPK/RAS pathway, there exists a plethora of protein–protein interactions (PPIs).
For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes …